Dataset Information

A chromatin basis for protein-RNA correlation in human cancer

ABSTRACT: This work describes a previously unreported link between the chromatin states and protein abundance in cancer. We curated and studied a novel cohort of human thyroid tumors that allowed us to identify chromatin features that directly regulate protein expression. We believe this is the first study to establish chromatin states that reflect protein abundances in human cancer.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Thyroid Gland

DISEASE(S): Thyroid Cancer

SUBMITTER: Akshay Sanghi

LAB HEAD: Michael Snyder

PROVIDER: PXD023078 | Pride | 2021-11-02

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Instrument1_sample10_Fr.msf	Msf
	Instrument1_sample10_Fr01.raw	Raw
	Instrument1_sample10_Fr02.raw	Raw
	Instrument1_sample10_Fr03.raw	Raw
	Instrument1_sample10_Fr04.raw	Raw

Items per page:

1 - 5 of 313

Publications

Chromatin accessibility associates with protein-RNA correlation in human cancer.

Sanghi Akshay A Gruber Joshua J JJ Metwally Ahmed A Jiang Lihua L Reynolds Warren W Sunwoo John J Orloff Lisa L Chang Howard Y HY Kasowski Maya M Snyder Michael P MP

Nature communications 20210930 1

Although alterations in chromatin structure are known to exist in tumors, how these alterations relate to molecular phenotypes in cancer remains to be demonstrated. Multi-omics profiling of human tumors can provide insight into how alterations in chromatin structure are propagated through the pathway of gene expression to result in malignant protein expression. We applied multi-omics profiling of chromatin accessibility, RNA abundance, and protein abundance to 36 human thyroid cancer primary tum ...[more]

PMID: 34593797

Similar Datasets

Project description:Colorectal cancer is the second leading cause of cancer death worldwide, and the incidence of this disease is expected to increase as global socioeconomic changes occur. Immune checkpoint inhibition therapy is effective in treating a minority of colorectal cancer tumors; however, microsatellite stable tumors do not respond well to this treatment. Emerging cancer immunotherapeutic strategies aim to activate a cytotoxic T cell response against tumor-specific antigens, presented exclusively at the cell surface of cancer cells. These antigens are rare and are most effectively identified with a mass spectrometry-based approach, which allows the direct sampling and sequencing of these peptides. While the few tumor-specific antigens identified to date derived from coding regions of the genome, recent findings indicate that a large proportion of tumor-specific antigens originate from allegedly noncoding regions. Here, we employed a novel proteogenomic approach to identify tumor antigens in a collection of colorectal cancer-derived cell lines and biopsy samples consisting of matched tumor and normal adjacent tissue. The generation of personalized cancer databases paired with mass spectrometry analyses permitted the identification of more than 30 000 unique MHC I-associated peptides. We identified 19 putative tumor-specific antigens in both microsatellite stable and unstable tumors, over two-thirds of which were derived from non-coding regions. Many of these peptides were derived from source genes known to be involved in colorectal cancer progression, suggesting that antigens from these genes could have therapeutic potential in a wide range of tumors. These findings could benefit the development of T cell-based vaccines, in which T cells are primed against these antigens to target and eradicate tumors. Such a vaccine could be used in tandem with existing immune checkpoint inhibition therapies, to bridge the gap in treatment efficacy across subtypes of colorectal cancer with varying prognoses.